A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers
A Clinical Pharmacology Study to Determine the Pharmacokinetic , Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of A-831 in Otherwise Healthy Male Hepatitis C Carriers With Compensated Liver Disease
  • Phase

    Phase 1/Phase 2
  • Study Type

  • Status

  • Intervention/Treatment

    azd7295 ...
  • Study Participants

The purposes of this study are:

to determine the safety and tolerability of multiple doses of A-831 at various doses
to determine how multiple doses of A-831 are distributed through the bloodstream
to determine if A-831 reduces the amount of Hepatitis C virus in the blood
Study Started
Aug 31
Primary Completion
Mar 31
Study Completion
May 31
Last Update
Sep 29

Drug A-831


Inclusion Criteria:

Volunteers will be males of any race aged 18-60 years with a BMI between 18 and 32 kg/m2 at the time of the screening medical
Volunteers who have given their written informed consent to participate in the study
Volunteers who are willing and able to comply with the protocol and study procedures
Volunteers who have a diagnosis of chronic hepatitis C infection and are in good health (other than history of Hepatitis C infection)

Exclusion Criteria:

Voulnteers with concurrent medical conditions or taking concurrent medications
No Results Posted